London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
LONDON, UK / ACCESSWIRE / May 5, 2022 / Apollon Formularies plc (AQSE:APOL) (“Apollon” or the “Company”), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE:AION) (“Aion”), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that Apollon has acquired certain intellectual property from AI Pharmaceuticals Ltd., a wholly owned Jamaican subsidiary of Aion.
Under the terms of the Agreement, Apollon will acquire the following patents and all associated supporting data including the pre-clinical testing results from BIOENSIS.
Compositions and Methods for Treatment of Cancers.
Compositions and Methods for Treatment of Inflammation.
Methods for Treatment of Human Cancers using Mushroom Compositions.
Methods for Treatment of Human Cancers using Cannabis Compositions.
Apollon has purchased the patents from Aion via a cash payment of £95,957.18 and the issuing of 4,348,679 ordinary shares in the Company. These ordinary shares will be subject to a complete trading restriction for a period of six (6) calendar months from the date of the stock transfer. After the six (6) month restriction period, twenty percent (20%) of such stock received will become eligible for trading, and an additional twenty percent (20%) will be tradable at the end of each following three-month period, with all trading restrictions being fully removed at the end of eighteen (18) months.
Read more: https://www.digitaljournal.com/pr/apollon-acquires-intellectual-property-from-aion#ixzz7SPkaxhbY
Apollon Formularies
@apollon_uk
·
29m
(3/3) $APOL has purchased the patents via a cash payment & the issuing of ordinary Company shares. In addition, #APOL will pay Aion a 4% royalty fee of Net Revenues on all products produced & sold that are based on the purchased patents
https://twitter.com/apollon_uk
Interesting ... and the price seems reasonable given the combo potential (different therapeutic pathways). Suspect that Aion may need the cash / didn't have it to splash on the joint compound development.